Your browser is no longer supported. Please, upgrade your browser.
ORGO Organogenesis Holdings Inc. daily Stock Chart
Organogenesis Holdings Inc.
Index- P/E- EPS (ttm)-0.06 Insider Own54.77% Shs Outstand105.04M Perf Week20.38%
Market Cap529.18M Forward P/E- EPS next Y-0.16 Insider Trans12.06% Shs Float12.50M Perf Month27.96%
Income-4.90M PEG- EPS next Q-0.05 Inst Own4.70% Short Float2.88% Perf Quarter14.16%
Sales306.10M P/S1.73 EPS this Y52.70% Inst Trans15.06% Short Ratio1.33 Perf Half Y52.10%
Book/sh0.62 P/B8.19 EPS next Y-23.10% ROA-2.20% Target Price- Perf Year-16.31%
Cash/sh0.35 P/C14.50 EPS next 5Y- ROE-10.00% 52W Range2.47 - 7.01 Perf YTD5.61%
Dividend- P/FCF- EPS past 5Y- ROI-20.10% 52W High-25.42% Beta1.18
Dividend %- Quick Ratio1.50 Sales past 5Y- Gross Margin73.20% 52W Low111.47% ATR0.41
Employees835 Current Ratio1.90 Sales Q/Q56.80% Oper. Margin2.00% RSI (14)70.51 Volatility7.64% 8.71%
OptionableNo Debt/Eq1.75 EPS Q/Q256.40% Profit Margin-1.60% Rel Volume3.74 Prev Close5.08
ShortableNo LT Debt/Eq1.52 EarningsNov 09 AMC Payout- Avg Volume269.77K Price5.23
Recom1.20 SMA2028.07% SMA5030.57% SMA20035.82% Volume298,692 Change2.91%
Jan-10-20Initiated SVB Leerink Outperform $9
Aug-26-19Resumed Credit Suisse Outperform $9 → $10
May-02-19Initiated Credit Suisse Outperform $9
Apr-17-19Initiated Oppenheimer Outperform $11
Apr-11-19Initiated SunTrust Buy $11
Nov-23-20 12:24AM  
Nov-18-20 02:11AM  
Nov-13-20 12:45AM  
Nov-10-20 05:40PM  
Nov-09-20 05:01PM  
Nov-02-20 04:30PM  
Oct-15-20 01:30PM  
Oct-14-20 04:30PM  
Oct-12-20 03:30PM  
Sep-17-20 04:05PM  
Sep-03-20 04:05PM  
Sep-02-20 12:05PM  
Aug-24-20 04:05PM  
Aug-11-20 02:30AM  
Aug-10-20 06:25PM  
Aug-03-20 12:31PM  
Jul-23-20 04:05PM  
Jul-15-20 07:30AM  
Jun-29-20 07:30AM  
Jun-05-20 01:11PM  
May-26-20 12:06PM  
May-12-20 12:30PM  
May-11-20 08:25PM  
Apr-13-20 04:05PM  
Apr-08-20 04:05PM  
Mar-30-20 07:38AM  
Mar-25-20 09:15AM  
Mar-13-20 10:49AM  
Mar-09-20 04:05PM  
Feb-21-20 07:30AM  
Feb-11-20 05:43AM  
Jan-27-20 10:37AM  
Jan-23-20 04:05PM  
Jan-13-20 07:00AM  
Nov-21-19 10:04PM  
Nov-20-19 07:25AM  
Nov-19-19 04:01PM  
Nov-12-19 04:05PM  
Nov-11-19 11:22AM  
Oct-11-19 04:05PM  
Oct-05-19 09:00AM  
Sep-17-19 07:30AM  
Sep-06-19 04:06PM  
Aug-19-19 04:57PM  
Aug-09-19 01:24PM  
Jul-22-19 04:15PM  
Jul-08-19 08:00AM  
Jul-01-19 07:30AM  
May-10-19 12:17PM  
May-01-19 08:30AM  
Apr-30-19 08:30AM  
Apr-02-19 07:30AM  
Apr-01-19 08:30AM  
Mar-18-19 04:05PM  
Mar-14-19 04:05PM  
Mar-12-19 09:00AM  
Mar-11-19 07:30AM  
Mar-04-19 09:00AM  
Feb-25-19 08:00AM  
Jan-24-19 10:00AM  
Jan-07-19 05:54PM  
Organogenesis Holdings Inc., a regenerative medicine company, focuses on the development, manufacture, and commercialization of solutions for the advanced wound care, and surgical and sports medicine markets primarily in the United States. The company's advanced wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for treating DFUs; PuraPly AM to address biofilm across a range of wound types; and Affinity and NuShield to address various wound sizes and types. Its surgical and sports medicine products comprise ReNu for in-office joint and tendon applications; NuCel for bony fusion in the spine and extremities; NuShield and Affinity for surgical applications in targeted soft tissue repairs; and PuraPly AM for the surgical treatment of open wounds. The company's pipeline products include TransCyte for the treatment of second- and third-degree burns; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; Novachor for the treatment of chronic and acute wounds; Gintuit for the treatment of mucogingival conditions in adults; and PuraPly XT and PuraPly MZ for the treatment of chronic and acute wounds, as well as for surgical treatment of open wounds. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician offices. The company sells its products through direct sales representatives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Avista Capital Managing MemberDirectorNov 19Buy4.9736,127179,61329,921,676Nov 19 07:14 PM
Avista Capital Managing MemberDirectorNov 18Buy4.6845,378212,51929,885,549Nov 19 07:14 PM
NUSSDORF GLENN HDirectorNov 17Buy3.25347,1531,128,24768,794,976Nov 19 04:55 PM
NUSSDORF GLENN HDirectorNov 17Buy3.25486,0001,579,50068,447,823Nov 19 04:55 PM
Ades Alan A.DirectorNov 17Buy3.25347,1531,128,24768,794,976Nov 19 04:53 PM
Ades Alan A.DirectorNov 17Buy3.25486,0001,579,50068,447,823Nov 19 04:53 PM
Avista Capital Managing MemberDirectorNov 17Buy3.264,322,65714,108,54029,840,171Nov 19 07:14 PM
KATZ MICHAEL W10% OwnerNov 17Buy3.2520,82967,69434,432Nov 19 05:21 PM
MACKIE WAYNE DDirectorNov 17Buy3.2542,726138,860161,290Nov 19 05:10 PM
Leibowitz Arthur SDirectorNov 17Buy3.256,94322,56530,507Nov 19 05:05 PM
Grow BrianChief Commercial OfficerApr 14Option Exercise1.701,1501,9553,279Apr 16 06:28 PM
Avista Capital Managing MemberDirectorMar 16Buy3.9875,000298,13325,517,514Mar 16 09:47 PM
Avista Capital Managing MemberDirectorMar 13Buy4.31135,000581,28325,442,514Mar 16 09:47 PM
Avista Capital Managing MemberDirectorMar 12Buy3.86332,3491,281,54125,307,514Mar 16 09:47 PM
Gillheeney Gary S.President and CEOFeb 05Option Exercise1.70397,900676,430397,900Feb 07 06:56 PM
Montecalvo Antonio S.VP Health Policy & ContractingJan 21Option Exercise1.7030,45051,76538,932Apr 24 07:13 AM
Avista Capital Managing MemberDirectorNov 26Buy5.006,000,00030,000,00024,975,165Nov 27 04:17 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 All Rights Reserved.